Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR3419 in Relapsed/Refractory ALL
NCT01440179Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2011
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of coltuximab ravtansine in acute lymphoblastic leukemia (ALL), sponsored by Sanofi. Started Oct 2011; status: terminated.
02
Drugs
coltuximab ravtansine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01440179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440179.